GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (BSP:T1EV34) » Definitions » PB Ratio

Teva Pharmaceutical Industries (BSP:T1EV34) PB Ratio

: 1.08 (As of Today)
View and export this data going back to 2020. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-18), Teva Pharmaceutical Industries's share price is R$35.37. Teva Pharmaceutical Industries's Book Value per Share for the quarter that ended in Dec. 2023 was R$32.81. Hence, Teva Pharmaceutical Industries's PB Ratio of today is 1.08.

The historical rank and industry rank for Teva Pharmaceutical Industries's PB Ratio or its related term are showing as below:

BSP:T1EV34' s PB Ratio Range Over the Past 10 Years
Min: 0.45   Med: 1.28   Max: 2.66
Current: 1.97

During the past 13 years, Teva Pharmaceutical Industries's highest PB Ratio was 2.66. The lowest was 0.45. And the median was 1.28.

BSP:T1EV34's PB Ratio is ranked worse than
52.02% of 963 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs BSP:T1EV34: 1.97

During the past 12 months, Teva Pharmaceutical Industries's average Book Value Per Share Growth Rate was -4.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -9.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -14.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -15.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Teva Pharmaceutical Industries was 47.20% per year. The lowest was -24.10% per year. And the median was 16.70% per year.

Back to Basics: PB Ratio


Teva Pharmaceutical Industries PB Ratio Historical Data

The historical data trend for Teva Pharmaceutical Industries's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.53 0.43 0.65 0.78

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.64 0.59 0.67 0.78

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries PB Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's PB Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's PB Ratio falls into.



Teva Pharmaceutical Industries PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Teva Pharmaceutical Industries's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=35.37/32.805
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Teva Pharmaceutical Industries  (BSP:T1EV34) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Teva Pharmaceutical Industries PB Ratio Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (BSP:T1EV34) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Teva Pharmaceutical Industries (BSP:T1EV34) Headlines

No Headlines